The potential advantage of omapatrilat: Dual anti-fibrotic and anti-inflammatory effects in one single molecule

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 273-275

  Perlini, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [N [2 [[(DIPHENYLPHOSPHONO)METHYL]AMINO] 3 (4 BIPHENYLYL)PROPIONYL]AMINO]PROPIONIC ACID; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ENALAPRIL; OMAPATRILAT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DRUG MECHANISM; EDITORIAL; FIBROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; PRIORITY JOURNAL;

EID: 14044270788     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00007     Document Type: Editorial

References (23)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56:56-64.
2. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
3. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26:195-202.
4. Pichard AD, Gorlin R, Smith H, Ambrose J, Meller J. Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type. Evidence for an impaired coronary vascular reserve. Am J Cardiol 1981; 47:547-554.
5. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frolich ED. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77:18-22.
6. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 60:560-565.
7. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96:4065-4082.
8. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90:520-530.
9. Hara M, Matsumori A, Ono K, Kido H, Hwang MW, Miyamoto T, et al. Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 1999; 100:1443-1449.
10. Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA 1989; 86:6753-6757.
11. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643-650.
12. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997; 17:467-491.
13. Hardt SE, Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 2004; 63:500-509.
14. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101:812-818.
15. Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002; 7:317-322.
16. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH. Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. Hypertension 2002; 40:498-503.
17. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte- restricted inactivation of the atrial natriuretic peptide receptor guanyl cyclase-A. J Clin Invest 2003; 111:1399-1407.
18. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perlini S, et al. Serum N-terminal Pro brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyioidosis. Circulation 2003; 107:2440-2445.
19. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
20. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dalhöf B, et al. Different effects of antihypertrophic therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Results of a randomized trial. Circulation 2004; 110:552-557.
21. Pu Q, Amiri F, Cannon P, Schiffrin EL. Dual ACE/NEP inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005; 23:401-409.
22. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
23. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.